Please login to the form below

Not currently logged in
Email:
Password:

budesonide

This page shows the latest budesonide news and features for those working in and with pharma, biotech and healthcare.

Swedish biotech Calliditas signs China licensing deal for autoimmune candidate

Swedish biotech Calliditas signs China licensing deal for autoimmune candidate

Nefecon is a novel oral formulation of the corticosteroid budesonide which targets the active ingredient to B cells in the lower small intestine and control the output of IgA antibodies.

Latest news

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... It was

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    while AZ’s PT010 (glycopyrronium/formoterol fumarate/budesonide) triple has phase III data in hand is up for regulatory filings in Asia this year and in the US and Europe in

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    budesonide - showing that the product achieved significant improvements in a range of lung function tests in COPD patients compared to various two-drug combinations.

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The benefits of Trelegy/Elebrato - delivered using the company's Ellipta dry powder inhaler - are its ability to improve lung function compared to AstraZeneca's ICS/LABA combination Symbicort (budesonide/formoterol)

  • Smart solutions Smart solutions

    It is not just GSK that is under pressure. The likes of AstraZeneca’s Symbicort (budesonide and formoterol), Merck &Co’s Dulera (formoterol and mometasone) and Teva’s Qvar (beclometasone) are

More from news
Approximately 1 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    410. AstraZeneca (UK). Cilag J&J (US). Asset acquisition. Rhinocort (budesonide) nasal spray for rhinitis, global rights excluding US.

  • Deal Watch November 2015 Deal Watch November 2015

    So selling off the US rights for Entocort (budesonide), in the non-strategic field of mild to moderate Crohn's disease seems like small beer but the $380m paid by Perrigo ... 386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed

  • Pharma deals in August 2015 Pharma deals in August 2015

    Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan

  • Pharma deals in July 2015 Pharma deals in July 2015

    Secondly, AZ sold Entocort (budesonide) global rights except the US to Tillotts, for $215m representing a sales multiple of 4. ... 250+. AstraZeneca / Tillotts. Product acquisition. Entocort (budesonide) marketed. 215. Occuleve / Allergan.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - develop and commercialise. 265. Meritage Pharma/ Shire. Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics